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Clinical practice guidelines generally, and some WHO guidelines specifi cally, have 
been criticized for not being based 
on the best available evidence, for 
being exposed to undue infl uence by 
industry and experts who participate in 
guideline panels, and for not adhering 
to guidelines for preparing guidelines 
[1–7]. Guidance that is not informed 
by the best available evidence or by 
statements that the available evidence is 
of low quality can harm patients, waste 
limited resources, and hinder research 
to address important uncertainties [8].
While there is broad agreement that 
rigorous and transparent methods 
should be used [9–12], rigorous 
development of guidelines can take two 
years or more [13,14]. This timeframe 
is not practical for providing rapid 
advice, for example for emerging 
infectious diseases such as avian 
infl uenza (H5N1 infection) or severe 
acute respiratory syndrome (SARS). 
Indeed, one of the most frequently 
cited weaknesses in guideline 
development is the length of time 
that it takes to develop a guideline 
[15]. Organizations including the 
National Centre for Health and Clinical 
Excellence in the United Kingdom and 
the National Institutes of Health in the 
United States are investigating ways of 
streamlining guidelines development 
processes [16,17].
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Summary
Emerging health problems require 
rapid advice. We describe the 
development and pilot testing of a 
systematic, transparent approach used 
by the World Health Organization 
(WHO) to develop rapid advice 
guidelines in response to requests 
from member states confronted with 
uncertainty about the pharmacological 
management of avian infl uenza A 
(H5N1) virus infection. We fi rst searched 
for systematic reviews of randomized 
trials of treatment and prevention 
of seasonal infl uenza and for non-
trial evidence on H5N1 infection, 
including case reports and animal 
and in vitro studies. A panel of clinical 
experts, clinicians with experience in 
treating patients with H5N1, infl uenza 
researchers, and methodologists was 
convened for a two-day meeting. 
Panel members reviewed the evidence 
prior to the meeting and agreed on 
the process. It took one month to put 
together a team to prepare the evidence 
profi les (i.e., summaries of the evidence 
on important clinical and policy 
questions), and it took the team only 
fi ve weeks to prepare and revise the 
evidence profi les and to prepare draft 
guidelines prior to the panel meeting. 
A draft manuscript for publication was 
prepared within 10 days following 
the panel meeting. Strengths of the 
process include its transparency and the 
short amount of time used to prepare 
these WHO guidelines. The process 
could be improved by shortening the 
time required to commission evidence 
profi les. Further development is needed 
to facilitate stakeholder involvement, 
and evaluate and ensure the guideline’s 
usefulness.
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The WHO Advisory Committee for 
Human Research, an independent 
committee appointed by the Director-
General of the WHO, evaluated existing 
WHO and other guidance processes 
and suggested ways to improve WHO’s 
methods[18,19]. Consistent with 
these recommendations, a new model 
for developing WHO rapid advice 
guidelines was designed and tested 
through the development of guidelines 
for the pharmacological management 
of avian infl uenza A (H5N1) virus 
infection [20,21]. Because the 
approach to developing these rapid 
advice guidelines was novel for WHO, 
we describe the methods, the strengths 
of the approach, and ways in which this 
approach should be further developed.
The Process
In January 2006, the WHO decided 
to convene a rapid advice guidelines 
panel for the pharmacological 
management of H5N1 patients 
in response to requests for advice 
from frontline clinicians and public 
health professionals managing H5N1 
infections. The key steps and timeline 
for developing the guidelines are 
summarized in Box 1.
Group selection and composition. 
In selecting members for the panel, we 
wanted to include several important 
stakeholders: clinical, methodological, 
and basic science experts and member 
country representatives, including 
low- and middle-income countries. 
We used the WHO’s international 
network of response teams for viral 
pandemics and searched the medical 
literature for experts on H5N1 infection 
to identify panel members. We asked 
methodologists with experience in 
applying the Grading Recommendations 
Assessment, Development and 
Evaluation (GRADE) approach that 
was offi cially adopted by WHO to 
participate in the creation of evidence 
profi les and the guideline development 
process. Thirteen voting panel members 
supplemented by WHO experts 
participated in the panel meeting. We 
followed a thorough process to declare 
confl icts of interest (see Text S1 under 
Supporting Information).
Formulating questions and rating 
the importance of outcomes. The 
original questions were identifi ed 
by clinicians managing patients with 
H5N1 infections and refi ned by 
panel members. For each question an 
evidence profi le was prepared using 
the GRADE approach (Figure 1) [22]. 
The GRADE approach required the 
identifi cation of relevant outcomes to 
be included in each evidence profi le 
before developing the evidence 
profi les. Two reviewers identifi ed 
potentially important outcomes and 
this list was circulated to the panel 
chair, WHO staff, and the scientifi c 
reviewers by email for independent 
scoring of the relative importance 
of each outcome and identifi cation 
of additional potentially important 
outcomes. Outcomes were rated 
on a scale from 1–9; a rating of 7–9 
indicated that the outcome was critical 
for a decision or recommendation, 4–6 
indicated it was important, and 1–3 
indicated it was not important. The 
evidence profi les included only critical 
or important outcomes based on the 
mean value of the ratings by the panel 
members.
To obtain consumer input, the 
Cochrane Consumer Network was also 
invited to provide feedback through 
their electronic discussion list. We 
received only four responses, but 
despite reported diffi culties with the 
rating, the relative importance of the 
outcomes did not differ importantly 
from those of the panel and no 
additional outcomes were identifi ed.
Preparation of evidence profi les. 
An independent review team searched 
for systematic reviews and recent 
randomized trials (published in 
2005 or 2006) for the treatment and 
chemoprophylaxis of any infl uenza 
virus infection; and case series, animal 
studies, and in vitro studies for the 
treatment or chemoprophylaxis of 
H5N1 infection (from 1966). The 
team prepared evidence profi les using 
the GRADE profi ler software (v1.12, 
http:⁄⁄www.gradeworkinggroup.org) 
and proposed quality ratings according 
to the criteria in Box 2. The quality of 
outcomes measured in each animal 
study was judged based on whether (1) 
the pathogenicity of H5N1 virus was 
tested in the model (e.g., mortality), 
(2) statistical methods were adequate, 
and (3) a signifi cant effect was 
demonstrated.
A summary of the fi ndings for each 
question, including both trial evidence 
for non-H5N1 infl uenza and the 
available evidence for H5N1 infection, 
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Box 1. Key Steps in the Development of WHO Rapid Advice 
Guidelines 
Decision about the topic and focus of the guidelines January 2006
Decision about group composition and invitation of panel 
Formulation of questions and rating the importance 
of outcomes 
Literature search and preparation of evidence profi les February 17, 2006
WHO panel co-chair met with systematic reviewers
Panel chair and WHO panel co-chair corresponded 
electronically with systematic reviewers 
Review of evidence profi les and draft guidelines
Panel chair met with WHO panel co-chair and systematic 
reviewers
Panel meeting March 28–29, 2006
Information about methods and agreement on procedures 
at the meeting 
Declaration of confl icts of interest
Deliberation regarding the balance of benefi ts, harms, 
and costs for each question
Agreement on recommendations, including the strength 
of recommendations, and research priorities
Plans for updating the guidelines
Agreement on fi nal text of guidelines April 21, 2006
Circulation of draft guidelines
Approval by panel members
Approval/publication by WHO May 19, 2006
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was prepared for each question (Figure 
2) [21].
Panel meeting. Guideline group 
members and an independent expert 
received evidence profi les about two 
weeks prior to the meeting, including 
information about the applied 
methods. They were asked to identify 
any important missing evidence.
A draft of the guidelines was 
prepared by the WHO secretariat and 
the panel chair prior to the meeting. 
For the actual meeting, the agreed 
process rules were that: (1) Additional 
evidence would only be allowed at the 
meeting if it had been omitted from 
the evidence summaries, or was new 
and critical for decision making; (2) 
The GRADE approach would be used 
to grade the quality of evidence and 
the strength of recommendations 
[10,21]; (3) Recommendations 
would be based on a consensus of 
the panel and voting would be used 
if agreement could not be reached; 
(4) All panel members would be 
asked to consider their own and other 
confl icts during the discussion and 
decision making and to abstain from 
discussion and voting if necessary 
(see Supporting Information); (5) 
Subsequent interaction and discussion 
would take place through email but 
recommendations would not be 
changed after the meeting, except for 
minor wording changes or correction 
of factual errors.
Deliberation regarding the balance 
of benefi ts, harms, and costs. For each 
intervention considered, the panel 
formulated a recommendation based 
on the panel members’ judgments 
regarding the balance between the 
benefi ts, harms (adverse effects), 
burdens (e.g., taking medication daily), 
costs, and values and preferences 
(the desirability or preference that 
individuals exhibit for a particular 
outcome) of the intervention (see 
Supporting Information Text S1 for 
information on cost).
Recommendations were classifi ed 
as “strong” or “weak.” The panel was 
informed that strong recommendations 
should be interpreted as: (1) 
Most individuals should receive 
the intervention; (2) Most well-
informed individuals would want the 
recommended course of action and 
only a small proportion would not; (3) 
The intervention could unequivocally 
be used in policy making.
Weak recommendations were to 
be interpreted as: (1) The majority of 
well-informed individuals would want 
the suggested course of action, but an 
appreciable proportion would not; (2) 
Values and preferences related to this 
intervention are likely to vary widely; 
(3) Policy making will require extensive 
debates and involvement of many 
stakeholders.
The panel used the factors listed 
in Figure 3 as a basis for going from 
a strong to a weak recommendation. 
This information was recorded for 
recommendations where a formal vote 
was required, as illustrated in Figure 3.
Outcomes
It took approximately one month 
to put together a team to prepare 
the evidence profi les, but once the 
team was assembled it took only 
fi ve weeks to prepare and revise 
the evidence profi les and prepare 
draft guidelines prior to the panel 
meeting (Box 1). A draft manuscript 
for publication was prepared within 
10 days following the panel meeting. 
It took only two additional weeks to 
complete a fi nal draft of the document 
(on April 21, 2006) that included 
all of the considered evidence and 
recommendations.
Overall the quality of the underlying 
evidence for all recommendations 
was very low because the evidence was 
based upon observational data from 
case series describing small numbers of 
patients infected with avian infl uenza 
A (H5N1) virus, laboratory research, 
or on extrapolation from randomized 
trials of treatment and prophylaxis for 
seasonal infl uenza. The panel evaluated 
the rationale for the quality rating 
during the meeting and subsequently 
via electronic correspondence. The 
reasons for considering the evidence 
to be of low or very low quality (i.e., 
for having little confi dence in the 
available estimates of effect) were: (1) 
the lack of direct evidence from trials 
among patients with H5N1 infection 
or exposure, (2) lack of evidence 
for important outcomes for H5N1 
infection that were not common or 
not measured in seasonal infl uenza 
trials, and (3) sparse data for other 
important outcomes. Additional factors 
and specifi c judgments regarding the 
quality of the evidence are included 
in detailed footnotes in the evidence 
profi les. The panel expressed concern 
about the categories used to grade 
the quality of evidence. For example, 
although the quality of the evidence 
for treatment and chemoprophylaxis 
with oseltamivir and zanamivir was very 
low for both, there was nonetheless 
a difference in the quality of the 
evidence within the categories for these 
two drugs.
The panel considered several 
different specifi c patient and exposure 
groups when considering the balance 
between benefi ts, harms, and costs 
for chemoprophylaxis. This led them 
to develop a risk categorization for 
exposure to assist decision makers in 
prioritizing use of antivirals [20,21].
Of the 27 recommendations, 15 were 
strong recommendations, but most 
(11) were strong recommendations 
against a specifi c intervention. 
The arguments for making strong 
recommendations for specifi c 
interventions, despite the low quality 
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Box 2. Key Quality Criteria  
The quality of evidence for each 
important or critical outcome is based 
on:
• the study design
• limitations of the studies (execution)
• consistency of the evidence across 
studies
• the directness (generalizability) of 
the evidence to the population, 
intervention, comparison, and 
outcomes
• the precision of the estimate or 
sparseness of data
Evidence was classifi ed as “high”, 
“moderate”, “low”, or “very low” 
based on these criteria and the 
following defi nitions: 
• High: Further research is very unlikely 
to change confi dence in the estimate 
of effect. 
• Moderate: Further research is likely 
to have an important impact on 
confi dence in the estimate of effect 
and may change the estimate.
• Low: Further research is very likely 
to have an important impact on 
confi dence in the estimate of effect 
and is likely to change the estimate.
• Very low: Any estimate of effect is very 
uncertain.
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of the available evidence, were 
the high risk of serious outcomes 
including death, the lack of alternative 
treatments, a low risk of serious adverse 
effects based on the available evidence, 
relatively low costs, and a possibility 
of benefi cial effects, although there 
is much uncertainty about these. The 
strong recommendation regarding 
treatment of H5N1 patients with 
oseltamivir required a vote (one panel 
member abstained and one voted for 
a weak recommendation). The main 
argument that led to voting about 
this recommendation was that it is 
uncertain whether the intervention 
does more good than harm in the 
face of very low-quality evidence. 
Only one other recommendation 
required voting. Other factors that 
infl uenced the recommendations, 
value judgments, and other directly 
relevant information are described 
in the remark sections following each 
recommendation [21].
Discussion
These guidelines were prepared in less 
than two months through an intense 
international collaboration, the use 
of electronic communication, and 
one panel meeting. However, it took 
one additional month initially to put 
together the team that prepared the 
evidence profi les.
There are at least two ways in which 
the time needed to prepare rapid 
advice could be shortened: fi rst, by 
identifying or establishing collaborating 
centres with the competency needed to 
prepare evidence profi les and second, 
by building up in-house capacity to 
reduce the time needed to organize a 
review team.
Strengths of the process. Strengths 
of the applied process include its 
transparency and the short amount of 
time used to prepare the guidelines. 
Guideline developers are increasingly 
using the GRADE approach because it 
includes transparent judgments about 
each of the key factors that determine 
the quality of evidence for each 
important outcome, and overall across 
outcomes for each recommendation 
[10,22,23]. In addition, the approach 
used in developing these guidelines 
included transparent consideration 
of the key factors that determine the 
strength of a recommendation. The 
rapid preparation of evidence profi les 
was possible because of the availability 
of high-quality systematic reviews of 
the evidence from seasonal infl uenza 
and the involvement of a review team 
with experience in preparing evidence 
profi les and relevant clinical expertise. 
In the absence of higher-quality 
direct evidence, the panel considered 
case reports, animal studies, and 
in vitro studies for H5N1, as well as 
the available indirect evidence from 
systematic reviews of clinical trials for 
seasonal infl uenza, systematically and 
transparently.
The broad representation of 
stakeholders in the guideline group 
allowed the inclusion of different 
perspectives for making informed 
judgments about the importance of 
outcomes, the quality of evidence, and 
the strength of recommendations. The 
publicly available evidence profi les 
facilitate adaptation of the guidelines 
to specifi c settings and updating of the 
guidelines, as well as contributing to 
transparency [13,21,24].
Limitations of the process. 
Limitations of this process relate to its 
very purpose: providing rapid advice. 
Thus, the time available for developing 
these guidelines did not permit 
detailed consideration of all clinical 
questions that clinicians may face. 
For example, the discussions about 
whether to use prophylactic antibiotics 
and which recommendations apply 
to situations of human-to-human 
transmission were short and, 
therefore, did not result in specifi c 
recommendations. It is unlikely that 
important evidence that would have 
led to different recommendations 
was missed given the nature of the 
problem; i.e., an emerging disease. In 
areas with an ample evidentiary base, 
evidence could be missed by relying 
on systematic reviews of the indirect 
evidence. However, this generally 
should not be the case when rapid 
advice is needed. It is not clear whether 
the differences the panel identifi ed 
within the category of very low-quality 
May 2007  |  Volume 4  |  Issue 5  |  e119
doi:10.1371/journal.pmed.0040119.g003
Figure 3. Decisions about the Strength of a Recommendation
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evidence are truly important for 
decision making, but panel members 
requested that this information should 
not be lost in translating the quality of 
evidence into the four categories based 
on the GRADE approach.
The total budget required for 
this guideline development project 
amounted to approximately 
US$150,000, for a focused guideline. 
This was made possible in part by 
limiting the number of meetings 
through the use of electronic 
communication tools. While this cost 
compares favourably with the cost of 
other guideline development processes, 
it remains out of reach for many 
countries trying to develop national 
rapid advice guidelines.
Involvement of stakeholders through 
consultation is limited by the rapid 
process. There are at least three ways 
in which stakeholder involvement 
could be improved. First, rapid 
consultations could be facilitated by 
establishing stakeholder groups and 
mechanisms for involvement such as 
those used by the National Centre 
for Health and Clinical Excellence. 
Second, evaluation and updating of the 
guidelines offer opportunities for more 
stakeholder involvement in revisions 
of the guidelines. Third, because the 
guidelines need to be adapted to 
specifi c settings, stakeholders could be 
involved in local adaptation processes.
Although research needs were 
identifi ed by the guideline panel, these 
do not provide clear guidance for what 
research should be prioritized to address 
the most important uncertainties about 
pharmacological management of H5N1 
infection. While this is partly due to the 
mandate that was given to the panel, 
recommendations for research should 
be viewed as an integral part of making 
recommendations.
Conclusion
In summary, we found that it is feasible 
to develop evidence-based guidelines 
systematically and transparently in as 
little as two months. The cost of doing 
this is prohibitively high for low- and 
middle-income countries and it would 
be wasteful for high-income countries 
to duplicate this process unnecessarily. 
WHO, or others developing rapid 
advice, can therefore provide an 
important service by using a robust 
and transparent process that simplifi es 
adaptation to specifi c settings. Further 
work is required to develop systematic 
processes for WHO to give even faster 
or immediate guidance for emerging 
infectious diseases. 
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